Autopsy report · NCT00843531
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
Cause of deathSlow enrollment
“Low Accrual”
Life of this trial
- Registered 4 months before it started.
- Ran for about 7 years 2 months before it stopped.
- 17 participants enrolled.
- Results were posted on the registry 4 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Conditions
- Neuroendocrine Tumors
- Interventions
- RAD001; erlotinib
- Participants
- 17
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.